Molecular Formula | C18H19BrN2S |
Molar Mass | 375.33 |
Solubility | DMSO: ≥10mg/mL |
Appearance | powder |
Color | light yellow to yellow |
Storage Condition | 2-8°C |
In vitro study | Fatostatin inhibits insulin-induced lipogenesis in 3T3-L1 cells and serum-independent growth of DU145 cells. Fatostatin inhibits activation of SREBPs in cells in tissue culture. Fatostatin inhibits cell proliferation, attachment-independent colony formation, and their in vitro invasion and metastasis in androgen-responsive LNCaP cells and androgen-insensitive C4-2B prostate cancer cells. In addition, fatostatin causes G2/M cell cycle arrest, induces apoptosis by increasing caspase-3/7 activity and caspase-3, PARP division. |
In vivo study | Fatostatin prevented the increase in body weight, blood glucose and liver fat accumulation in obese ob/ob mice, even though food intake was not controlled. Fatostatin significantly inhibited the growth of subcutaneous C4-2B tumors and reduced serum PSA levels. |
Hazard Symbols | Xn - Harmful |
Risk Codes | 22 - Harmful if swallowed |
WGK Germany | 1 |
1mg | 5mg | 10mg | |
---|---|---|---|
1 mM | 2.664 ml | 13.322 ml | 26.643 ml |
5 mM | 0.533 ml | 2.664 ml | 5.329 ml |
10 mM | 0.266 ml | 1.332 ml | 2.664 ml |
5 mM | 0.053 ml | 0.266 ml | 0.533 ml |
biological activity | Fatostatin HBr (Fatostatin A, 125B11) is an inhibitor of sterol regulatory element binding protein (drebp). It impairs SREBP-1 and SREBP-2 activation. |
Target | Value |